title: Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.
authors.affiliation: aDepartment of Internal Medicine bDepartment of Dermatology cHarold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
authors.forename: Arjun
authors.initials: A
authors.lastname: Gupta
authors.forename: Udayan
authors.initials: U
authors.lastname: Shah
authors.forename: Htet
authors.initials: H
authors.lastname: Khine
authors.forename: Travis
authors.initials: T
authors.lastname: Vandergriff
authors.forename: Thomas
authors.initials: T
authors.lastname: Froehlich
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D016736:Antiphospholipid Syndrome / Q000139:chemically induced*; D006801:Humans; D000074324:Ipilimumab / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D000077594:Nivolumab; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000074322:Antineoplastic Agents, Immunological; D000074324:Ipilimumab; D000077594:Nivolumab